300289SZSE
🚨 Material Event

Report on the Implementation of Major Asset Purchase

Lideman Co., Ltd.··13 pages

✨ AI Summary

Beijing Leadman Biochemistry Co., Ltd. has completed the acquisition of a 61.50% equity interest in Beijing Sansheng Xiangrui Biological Products Co., Ltd. through a cash transaction. The acquisition aims to expand the company's business scope and strengthen its market position. Following the transaction, Sansheng Xiangrui has become a controlled subsidiary of the company. The final transaction price for the 61.50% stake was determined to be 1.392975 billion RMB.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300289 Stock Abbreviation: Leadman Listing Venue: Shenzhen Stock Exchange

Beijing Leadman Biochemistry Co., Ltd.

Report on the Implementation of Major Asset Purchase

Independent Financial Advisor

July 2026

Company Statement

The Company and all directors and senior management guarantee that the content of this report is true, accurate, and complete, and assume corresponding legal liability for any false records, misleading statements, or major omissions in this report. The counterparty to this major asset restructuring has issued a letter of commitment, guaranteeing that the information provided for this major asset restructuring does not contain any false records, misleading statements, or major omissions, and assumes corresponding legal liability for the truthfulness, accuracy, and completeness of the information provided.

Any decision or opinion made by relevant regulatory authorities regarding this transaction does not represent a substantive judgment or guarantee of the value of the Company's shares or investor returns. Any statement to the contrary is a false and untrue statement.

After the completion of this transaction, the Company is responsible for changes in its operations and earnings; investment risks arising from this transaction shall be borne by investors themselves.

If investors have any questions regarding this report, they should consult their stockbroker, lawyer, professional accountant, or other professional advisor.

Table of Contents

Company Statement 1

Table of Contents 2

Definitions 3

Section 1 Overview of the Transaction 4

  1. Overview of the Transaction Plan 4

  2. Valuation and Pricing of Target Assets 4

  3. Nature of the Transaction 4

Section 2 Implementation of the Transaction 6

  1. Decision-making and Approval of the Transaction 6

  2. Handling of Asset Transfer or Delivery and Related Creditor-Debtor Matters 6

  3. Differences Between Actual Conditions and Previously Disclosed Information 7

  4. Changes in Directors, Supervisors, Senior Management, and Other Personnel 7

  5. Misappropriation of Funds or Assets by Controlling Shareholders or Related Parties, and Provision of Guarantees 7

  6. Performance of Related Agreements and Commitments 7

  7. Compliance and Risks of Subsequent Matters 8

Section 3 Conclusions of Intermediary Agencies 9

  1. Conclusion of Independent Financial Advisor 9

  2. Conclusion of Legal Advisor 9

Section 4 Documents Available for Inspection 11

  1. Documents Available for Inspection 11

  2. Inspection Locations 11

Definitions

Unless the context otherwise requires, the following abbreviations have the following meanings:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Sign in to read moreSee Pro pricing